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Background: Arterial access is a major site of bleeding complications after invasive coronary procedures. Among
strategies to decrease vascular complications, the radial approach is an established one. Vascular closure devices
provide more comfort to patients and decrease hemostasis and need for bed rest. However, the inconsistency of
data proving their safety limits their routine adoption as a strategy to prevent vascular complications, requiring
evidence through adequately designed randomized trials. The aim of this study is to compare the radial versus
femoral approach using a vascular closure device for the incidence of arterial puncture site vascular complications
among non-ST-segment elevation acute coronary syndrome patients submitted to an early invasive strategy.
Methods: ARISE is a national, multicenter, non-inferiority randomized clinical trial. Two hundred patients with
non-ST-segment elevation acute coronary syndrome will be randomized to either radial or femoral access using
a vascular closure device. The primary outcome is the occurrence of vascular complications at an arterial puncture
site 30 days after the procedure, including major bleeding, retroperitoneal hematoma, compartment syndrome,
hematoma ≥ 5 cm, pseudoaneurysm, arterio-venous fistula, infection, limb ischemia, arterial occlusion, adjacent
nerve injury or the need for vascular surgical repair.
Results: Enrollment was initiated in September 2012, and until October 2013 91 patients were included. The
inclusion phase is expected to last until the second half of 2014.
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Conclusions: The ARISE trial will help define the role of a vascular closure device as a bleeding avoidance strategy
in patients with NSTEACS.
Trial registration: ClinicalTrials.gov identifier: NCT01653587
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Access site complicationBackground
Antithrombotic therapy and percutaneous or surgical
myocardial revascularization procedures represent the
basis of hospital treatment for patients admitted with
non-ST-segment elevation acute coronary syndrome
(NSTEACS) [1,2]. However, the desired reduction of is-
chemic event recurrence is accompanied by an increased
incidence of bleeding [3,4]. Initially tolerated as an in-
herent complication of anti-ischemic treatment, major
bleeding is now recognized as a predictor of mortality
and adverse ischemic outcomes [5]. In fact, NSTEACS
patients who develop major bleeding have a two- to ten-
fold increase in mortality after a one-year follow-up
[6,7]. In the Acute Catheterization and Urgent Interven-
tion Triage Strategy (ACUITY) trial [8] involving 13,819
NSTEACS patients submitted to an early invasive strat-
egy and randomized for antithrombotic treatment with
unfractionated heparin (UFH) plus IIb-IIIa glycoprotein
receptor inhibitor (GPI), bivalirudin plus GPI or bivalir-
udin alone, the prognostic impact of major bleeding was
comparable to that of acute myocardial infarction (AMI)
in subsequent mortality (11.7% versus 9.1%, respectively)
[9]. Randomized clinical trials involving NSTEACS pa-
tients show major bleeding rates varying from 2% to 5%
[5,8], approaching the prevalence of refractory ischemia,
AMI or deaths observed in these studies. A publication
of the National Cardiovascular Data Registry Acute
Coronary Treatment and Intervention Outcomes Network
Registry Get with the Guidelines (NCDR ACTION
Registry-GWTG) [10], a representative registry of real
world practice, has evaluated 72,699 unselected patients
with NSTEACS and 48,943 patients with ST-segment-
elevation AMI evaluated at 360 North American hospi-
tals between January 2007 and June 2009. Authors have
reported a major bleeding rate of approximately 9%
among NSTEACS patients and 12% among those with
ST-segment-elevation AMI, primarily influenced by the
presence of comorbidities such as older age, female gen-
der, chronic renal failure, as well as the use of invasive
techniques [9,11].
Bleeding and vascular complications related to
arterial access
Because arterial puncture followed by sheath insertion
using the modified Seldinger technique [12] has becomethe standard method used to perform invasive cardiovas-
cular procedures, vascular access has become a major
site of bleeding complications [13]. According to the
Global Registry of Acute Coronary Events (GRACE), the
most frequent bleeding sites were gastrointestinal (31.5%)
and those related to vascular access (23.8%), with the latter
being more prevalent among patients submitted to invasive
strategies [11]. In a joint analysis of 17,393 acute coronary
syndrome (ACS) patients submitted to percutaneous cor-
onary intervention (PCI) and included in the studies Ran-
domized Evaluation in PCI Linking Angiomax to Reduced
Clinical Events (REPLACE) - 2, ACUITY and Harmonizing
Outcomes with RevascularIZatiON and Stents in Acute
Myocardial Infarction (HORIZONS-AMI), the bleeding
prevalence by Thrombosis in Myocardial Infarction (TIMI)
criteria was 5.3%, of which 2.1% (38.6%) were related to
vascular access [14].
Strategies to prevent bleeding and vascular complications
Radial technique
Among the strategies to decrease vascular complica-
tions after invasive coronary procedures, the radial
approach is an established one [15,16]. Although it has
been adopted by only a few centers, it provides more
comfort to patients, allows early ambulation, decreases
hospital stay and shows less vascular puncture site com-
plications [17]. In a comparative randomized trial be-
tween radial and femoral techniques involving 7,021 ACS
patients submitted to invasive techniques, both tech-
niques were shown to be safe and effective for PCI,
with similar incidences of death, AMI, stroke and major
bleeding at 30 days (3.7% versus 4.0%; P = 0.50) [18].
However, the radial approach displayed significantly de-
creased vascular complications, including pseudoaneur-
ysm, large hematomas, arterio-venous fistula and limb
ischemia requiring surgical intervention (1.4% versus
3.7%; P < 0.0001).
Given the small number of training centers that use
the radial technique, the uncertainties concerning the
learning curve which would be associated with a higher
failure rate and more radiological exposure, and the lack
of large-scale multicenter studies that can reproduce the
excellent results obtained by highly experienced centers,
the femoral approach remains the most popular for inva-
sive coronary procedures [19].
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Although the real prognostic significance of preventing
vascular access complications and minor bleedings has
not yet been established, the occurrence of vascular ac-
cess complications is associated with poor patient adher-
ence to the antiplatelet therapy after hospital discharge
and is a major and known predictor of ischemic com-
plication recurrence [20]. Strategies to decrease fem-
oral access vascular complications have been frequently
evaluated and implemented, such as the use of smaller
diameter endovascular devices, early arterial sheath re-
moval, fluoroscopy or ultrasound-guided femoral puncture
and the choice of antithrombotic agents with better safety
profiles [8,21-23].
Since 1995, percutaneous femoral vascular closure de-
vices (VCD) were introduced to decrease vascular com-
plications, hemostasis and ambulation times of patients
submitted to invasive procedures by femoral access. Al-
though these devices have been rapidly incorporated into
interventionist practice, they have shown conflicting
results regarding their safety and efficacy, motivating
a class III recommendation as a strategy to decrease
vascular complications in a recent position taken by the
American Heart Association [24].
Three meta-analyses that compared VCD and manual
compression from 2004 have reported conflicting results
regarding their safety. Koreny et al. [25] grouped data
from 30 randomized trials involving 4,000 patients and
showed a decrease of 17 minutes to obtain hemostasis
with VCD, at the expense of a non-significant increase in
hematomas, bleeding, arterio-venous fistulas and pseu-
doaneurysms. Nikolsky et al. [26] identified 30 random-
ized and observational studies in 37,066 patients where
VCD were associated with increased vascular complica-
tions compared with manual compression, particularly
using the VasoSeal (Datascope Corp., Montvale, NJ) device.
Conversely, Vaitkus et al. [27] described in a meta-analysis
involving 15 randomized trials and 5,084 patients a de-
crease in vascular complications favoring the new technol-
ogy, particularly when using AngioSeal (St. Jude Medical,
St. Paul, MN) and Perclose (Abbott Vascular, Redwood
City, CA) devices, an observation that has been validated
by results of large multicenter observational registries pub-
lished subsequently [28,29].
In summary, different VCD, although not demonstrating
a class effect, clearly provide more comfort to patients, de-
creasing hemostasis and bed rest time. However, the incon-
sistency of data proving their safety limits their routine
adoption as a strategy to prevent vascular complications,
requiring evidence through adequately designed random-
ized studies. The hypothesis of this investigation is that
among NSTEACS patients submitted to an early invasive
strategy and randomized to the femoral or radial approach,
the percutaneous femoral vascular closure device woulddecrease the prevalence of vascular complications at the
puncture site, thus fulfilling the non-inferiority criteria




ARISE is a national, multicenter, non-inferiority random-
ized clinical trial comparing the radial versus femoral
approach using VCD to decrease vascular complications
related to an arterial puncture site among NSTEACS pa-
tients submitted to an early invasive strategy (Figure 1).
The primary outcome will be evaluated from random-
ization until 30 days after the invasive coronary procedure.
Outcomes
Primary outcome Vascular complications at the arterial
puncture site 30 days after the procedure (vascular com-
plications at the arterial puncture site include major
bleeding, retroperitoneal hematoma, compartment syn-
drome, hematoma ≥ 5 cm, pseudoaneurysm, arterio-
venous fistula, infection, limb ischemia, arterial occlusion
including asymptomatic occlusion, adjacent nerve injury or
the need for vascular surgical repair).
Secondary outcomes Individual components of the pri-
mary outcome, hematoma < 5 cm, major bleeding unre-
lated to the puncture site or myocardial revascularization
surgery, device success and crossover rate; cardiovascular
death, AMI or stroke at 12 months of evolution.
Study outcome definitions are listed in Table 1. A com-
mittee of clinicians will adjudicate all primary outcomes.
Patient population
Patients with NSTEACS will be managed with an invasive
approach if the following pre-requisites are met: (i) palp-
able radial artery with normal Allen or oximetry tests,
(ii) familiarity of the operator with the radial (≥ 100
transradial coronary procedures per year with a fem-
oral crossover rate ≤ 4%) and femoral techniques using
VCD (≥ 50 transfemoral coronary procedures per year
with AngioSeal) and (iii) agreement of the operator to
use the access route determined by the randomization
process (Table 2).
Procedures
Patients admitted with NSTEACS who are scheduled for
early invasive stratification by coronary angiography
followed by PCI, when applicable, will be evaluated in
terms of feasibility of both radial and femoral access
procedures. After the evaluation, with the patient meet-
ing all inclusion criteria and in the absence of exclusion
criteria, the patient may be included in the study after
signing the free and informed consent term.
Figure 1 ARISE study design: a randomized trial of the radial versus femoral approach using AngioSeal in non-ST-segment elevation
acute coronary syndrome (NSTEACS) patients.
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technique with VCD using a randomized sequence ob-
tained by computer algorithms and maintained in indi-
vidual, opaque and closed envelopes to conceal the
allocation process.
Both radial and femoral coronary angiography will be
performed using the Judkins technique and 6-French
diameter sheaths and pre-molded catheters for selective
catheterization of the left and right coronary arteries,
with the possibility to change the diameter of the devices
at the operator’s discretion. PCI will be indicated when
a lesion presumably responsible for the adjacent
clinical event is identified, with a stenosis diameter
severity ≥ 70% and a high probability of angiographic
success; PCI is ideally performed immediately after cor-
onary angiography and left ventriculography. Patients
with multiarterial coronary disease will be submitted to
PCI after agreement among the clinical cardiologist,
interventionist and heart surgeon. Procedures will be per-
formed according to recommendations and provisions of
current guidelines.
Arterial homeostasis
Radial approach The TR Band device (Terumo Medical
Corporation, Tokyo, JP) will be applied to obtain homeo-
stasis according to a previously validated protocol [31,32].
Immediately after procedure completion, the sheath is ini-
tially pulled by approximately 2 cm. The device is applied
to the patient with the green marker (located in the center
of the larger balloon) positioned exactly at the puncture
hole to aid in the location, visualization and control of pos-
sible bleeding. The balloon is inflated with an adequatesyringe injecting 15 mL of air with simultaneous and
total sheath removal, resulting in the absence of active
bleeding. From the fourth hour and at each subsequent
hour (fifth and sixth hours), 5 mL of air is slowly re-
moved, maintaining the balloon connected to the syringe
and controlling the plunger with the thumb. If bleeding
occurs during any stage of device removal, the volume of
air needed for homeostasis is again injected, repeating
the process 60 minutes later. If device failure occurs,
homeostasis will be obtained using a compressive dress-
ing with a porous elastic adhesive bandage (Tensoplast,
Smith & Nephew, London, UK).
Femoral approach The AngioSeal VCD, comprising an
absorbable collagen sponge and absorbable polymer
anchor with polylactic and polyglycolic acid connected
by an absorbable self-adjustable suture, will be used for
hemostasis. The device seals the arteriotomy hole be-
tween its two major components, the anchor and colla-
gen sponge. Hemostasis is primarily obtained through
mechanical means that is supplemented by collagen
platelet aggregation-inducing properties. The device will
be released according to the manufacturer’s recommen-
dations. First, an insertion introducer together with a
femoral artery arteriotomy hole locator will be posi-
tioned using a 0.035-inch-guidewire. Once blood reflow
by the distal edge of the set is confirmed, the guidewire
and insertion introducer are removed, keeping the arteriot-
omy locator in position. Next, the repair and hemostasis
device are inserted through the locator, exposing the an-
chor in the intraluminal space. The retreat of this second
set places the anchor against the internal puncture hole.
Table 1 Outcome definitions
Term Definition
Major bleeding Type 3 ((3a) bleeding with hemoglobin drop≥ 3 and < 5 g/dL, or packed red cells transfusion; (3b) bleeding
with hemoglobin drop≥ 5 g/dL, heart tamponade, bleeding requiring surgical intervention or bleeding
requiring intravenous inotropic drugs; (3c) intracranial hemorrhage; subcategories confirmed by autopsy,
imaging examinations or lumbar puncture; intraocular bleeding with vision impairment) or type 5 bleeding
((5a) possibly fatal bleeding, (5b) definitive fatal bleeding), according to the Bleeding Academic Research
Consortium definition [30].
Retroperitoneal hematoma Defined as building up of blood in the retroperitoneal space, caused by common femoral artery puncture
above the inguinal ligament, not obtaining an adequate hemostasis with consequent hematoma formation.
It is clinically manifested by dorsal, loin or inguinal pain, hypotension and/or hematocrit drop. Its diagnosis
has to be confirmed by abdominal ultrasound and/or CT.
Compartment syndrome Defined as abnormal tissue pressure increase inside an osteo-fascial compartment (considering in this analysis
the involvement of upper or lower limbs after arterial puncture), impairing nervous and muscular structure
irrigation, characterized by paresthesia, continuous pain, hypoesthesia, edema and stiffening of the affected
region, peaking with tissue necrosis and/or permanent functional injury if not adequately treated.
Hematoma Defined as localized collection of extravascular blood adjacent to the vessel, located in the topography of
the punctured artery used to perform the procedure.
Pseudoaneurysm Defined as a neocavity delimited by tissues adjacent to the injured vessel, fed by continuous blood flow
into and out, coming from the real lumen through a narrow neck connecting it to the inside of the cavity.
Diagnosis is determined by the presence of a pulsating bulge close to the puncture hole and is confirmed
by duplex scanning.
Arterio-venous fistula Defined as an abnormal and acquired communication between the arterial and venous surface caused by
the inadvertent puncture of a vein adjacent to the femoral or radial artery. Diagnosis is determined by the
presence of a continuous murmur or thrill at the puncture site and is confirmed by duplex scanning.
Infection Defined as the introduction and/or colonization of microorganisms in structures adjacent to the puncture
site and/or blood flow, predisposed by difficult access, repeated punctures, long introducer stay, multiple
catheters or a prolonged procedure. It is manifested by pain, hyperemia, local edema, adenopathy, fever
and/or leukocytosis with a shift to the left in the blood count.
Limb ischemia Defined as the presence of signs and/or symptoms such as local pain, paresthesia, paresis, skin pallor, cyanosis,
lack of pulse, cold extremities and/or muscle tenderness, caused by acute or sub-acute arterial occlusion and
confirmed by duplex scanning and/or arteriography.
Asymptomatic arterial occlusion Defined by blockade of the arterial blood flow without manifestations of disturbance of the cell mechanism
or insufficient tissue blood supply, not involving the terminal arterial segment (example: radial artery occlusion).
Adjacent nerve injury Defined by the presence of sensory and/or motor disorders in the limb through which the invasive coronary
procedure was performed, with persistence of signs and/or symptoms for≥ 24 hours, as a consequence of
direct injury by inadvertent nerve puncture, excessive compression or extrinsic compression by a hematoma
and/or a pseudoaneurysm.
Vascular surgical repair Defined by the presence of complications at the arterial puncture site requiring immediate or late
(first 15 days) surgical intervention to prevent and/or minimize sequelae to the affected limb.
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leased in the external puncture hole at the same time that
the anchor is sustained, resulting in effective and safe
hemostasis by preventing intra-arterial collagen release.
Total set removal is achieved using an absorbable suture
wrapped in a plastic tube to manually compact the colla-
gen sponge against the arterial wall. After the appearance
of an opaque mark, the suture is cut, the compacting tube
exerting compression may be removed, and the remaining
suture is cut close to the skin. If the device fails, homeosta-
sis will be obtained by manual compression. Patients will
be allowed to walk immediately after the radial procedure,
and one hour after bed rest in the supine position after the
femoral procedure with AngioSeal.
Table 3 illustrates possible antithrombotic treatment.
After successful PCI, anticoagulant therapy will be with-
drawn. Drugs such as angiotensin-converting enzymeinhibitors or angiotensin receptor blockers, beta blockers
and statins will be prescribed according to current sec-
ondary prevention guidelines.
Electrocardiogram (ECG), CK-MB and/or troponin,
glucose, creatinine, sodium, potassium, blood count and
coagulation tests shall be obtained before patient ran-
domization. Biomarkers (CK-MB and/or troponin) shall
be checked between 12 and 24 hours after the proced-
ure. ECG shall be performed soon after the procedure
and within 12 to 24 hours after the procedure or
when a new ischemic event is suspected. Hemoglobin and
hematocrit dosage will be required in the presence of
vascular complications or bleeding. Vascular and systemic
complications related to the arterial vascular access will be
evaluated in the interval between procedure completion,
hospital stay and the first 30 days of evolution, through a
scheduled visit. Other outcomes will be considered until
Table 2 Eligibility criteria
Inclusion criteria Non-ST-segment elevation acute coronary syndrome patients (ischemic symptoms suspicious of non-ST-segment elevation
ACS (unstable angina or non-ST-segment elevation AMI) defined as clinical presentation compatible with a new manifestation
or worsening of chest pain characteristic of ischemia at rest or at minimum effort, lasting more than 10 minutes, and at least
one of the following items: (a) ECG changes compatible with new ischemia (ST-segment depression of at least 1 mm, transient
ST-segment elevation, ST-segment elevation≤ 1 mm or T wave inversion > 3 mm in at least two contiguous shunts); (b) cardiac
enzymes (CK-MB or troponin T or I) above the upper normality range limit; (c) patients > 60 years of age without ECG or
myocardial necrosis marker changes; however, with previous documentation of coronary atherosclerotic disease, confirmed
by previous hospitalization due to AMI, previous percutaneous or surgical myocardial revascularization procedure, significant
coronary atherosclerotic disease confirmed by coronary angiography or positive functional test for myocardial ischemia)
Intention to submit patient to an early invasive strategy consisting of coronary angiography immediately followed by PCI,
when applicable, in the first 72 hours after admission
Patient informed about the nature of the study and agreeing with its general terms and having signed the informed
consent, as approved by the Research Ethics Committee of the respective center
Patient eligible for coronary angiography and both radial and femoral PCI with the following pre-requisites: (a) palpable
radial artery with the Allen or normal oximetry tests, (b) familiarity of the operator with the radial and femoral techniques
using AngioSeal, (c) agreement of the operator to use the access route determined by the randomization process
Exclusion criteria Less than 18 years of age
Pregnancy
Chronic use of vitamin K antagonists, direct thrombin inhibitors or oral factor Xa antagonists
Hypersensitivity to antiplatelet and/or anticoagulant drugs
Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets
count < 100,000 mm3)
Uncontrolled systemic hypertension
Cardiogenic shock
Previous myocardial revascularization surgery with≥ 1 internal mammary or radial artery graft
Documented chronic peripheral arterial insufficiency preventing the use of the femoral technique
Severe concomitant disease with life expectancy below 12 months
Participation in drug or device investigative clinical trials in the last 30 days
Indication of elective percutaneous coronary intervention to be performed at a moment different from immediately after
coronary angiography
Medical, geographic or social conditions impairing participation in the study or inability to understand and sign the
informed consent term
Table 3 Adjunct antithrombotic therapy
Site Emergency unit Catheter lab Coronary unit and/or ward Home use duration
Drug
Aspirin 300 mg orally No 100 mg per day orally 100 mg per day orally, indefinitely
Clopidogrel 600 mg orally No 75 mg per day orally 75 mg per day orally, 12 months
Prasugrel 60 mg orally No 10 mg per day orally 10 mg per day orally, 12 months
Ticagrelor 180 mg orally No 90 mg twice daily orally 90 mg twice daily orally, 12 months
Enoxaparin 1 mg per kg SC 0.3 mg per kg IV if the last dose is 8 to
12 hours 0.5 to 0.75 mg per kg IV if the
last dose is >12 hours
1 mg per kg SC twice daily No
Fondaparinux 2.5 mg SC 85 UI per kg IV UFH or 60 UI per kg IV UFH
if GPI is scheduled
2.5 mg/SC/day No
Abciximab No Intravenous loading dose of 0.25 mg per kg 0.125 mcg per kg per min for
12 hours, IV, without using HNF
No
Tirofiban No Intravenous loading dose of 25 mcg per kg 0.15 mcg per kg per min for 12 to
18 hours, IV, without using HNF
No
GPI, IIb-IIIa glycoprotein receptor inhibitor; UFH; unfractionated heparin, IV, intravenous; SC subcutaneous.
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telephone call regarding cardiovascular death, AMI or
stroke, at 12 months.
Statistical analysis
The primary analysis of the study is a non-inferiority
comparison between the radial approach and femoral
approach using VCD to decrease vascular complications
at the arterial puncture site, in all randomized patients,
based on the intention-to-treat principle.
Estimating a vascular complication rate pre-specified
in the primary outcome of approximately 3% for the ra-
dial technique [19,32] and 12% for the femoral technique
[26-31] and determining a non-inferiority margin of 0.15
based on historical data [18,19] with an alpha level of
0.05 and a beta level of 0.10, the minimum estimated
sample size per group was established as 97 individuals.
Twenty additional patients may be added to the final
population to correct any subsequent loss of follow-up.
This non-inferiority margin was derived from a trial that
demonstrate the benefit of radial approach on the reduc-
tion of major vascular complications (hazard ratio, 0.37;
95% confidence interval, 0.27 to 0.52) as compared with
femoral approach [18]. The non-inferiority margin of
0.15 was chosen in order to avoid a loss of greater than
half the lower bound of the 95% confidence interval
(0.27). The non-inferiority of the femoral approach with
VCD will be declared if the lower confidence interval
limit of 95% of the difference of both techniques does
not include the specified inferiority margin value.
Categorical data will be presented as frequencies and
group percentage and will be compared by chi-squared
or Fisher’s exact tests. Continuous variables will be
expressed as means and standard deviation and will
be compared by Student’s t-test. Statistical analyses will be
performed using Statistical Package for the Social Sciences
for Windows (version 16.0; SPSS, Chicago, IL, USA).
The study was approved by the Dante Pazzanese Insti-
tute of Cardiology ethical committee, predicting and
validating the Santa Casa de Marília as a co-participating
institution. No extramural funding will be used to sup-
port this work. The authors are solely responsible for
the design and conduct of this study, all study analyses
and drafting and editing of the paper.
Results and discussion
Study status
Enrollment was initiated in September 2012, and until
October 2013 91 patients were included. The inclusion
phase is expected to last until the second half of 2014.
Conclusions
Despite the proven efficacy of the radial approach in
reducing vascular complications at the puncture site, thefemoral approach remains the preferred technique at
many centers worldwide. The ARISE trial will help
define the role of vascular closure devices as a bleeding
avoidance strategy in patients with NSTEACS.
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